To truly discover Rising Stars in a rapidly changing landscape that may no longer recognise traditional metrics – publication numbers, qualifications, involvement in trials, etc – with the
Among the infinite symposia, webinars, and white papers on this topic, “KOL identification” and “KOL mapping” can find themselves melting together in a gelatinous jargon
As the ASCO congress drew to a close, Johnson & Johnson filed for FDA approval of its BCMA-targeting CAR-T therapy Carvykti for use earlier in the treatment pathway fo
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas
